Calliditas

Calliditas therapeutics

This biopharmaceutical company develops and commercialises medicines for patients with rare renal and hepatic diseases.

Ultragenyx

This biopharmaceutical company develops and commercialises therapies for patients with serious rare and ultra-rare genetic diseases.

Calluna Pharma

This clinical-stage company develops monoclonal antibodies to treat inflammatory and fibrotic diseases for patients with conditions like idiopathic pulmonary fibrosis and chronic kidney disease.

Chinook Therapeutics

This biopharmaceutical company develops precision medicines for patients with rare and severe chronic kidney diseases.

VectivBio

This company develops biopharmaceutical treatments for severe rare gastrointestinal conditions, including short bowel syndrome, for patients with orphan diseases.

River Renal

This clinical-stage biotechnology company develops novel pharmaceutical therapies targeting orphan renal diseases for patients with unmet medical needs.

Veratx

The company develops medicines for patients with autoimmune diseases, focusing on the treatment of kidney conditions such as IgA nephropathy.

Sanifit

This biopharmaceutical company develops treatments for progressive vascular calcification disorders in patients with end-stage kidney disease.